In order to have new drugs to help with cancers and rare diseases, we have to first try them out in Clinical Trials. The design process of clinical trials is somewhat cumbersome and is often inherently controversial. We want to make sure that the trial gives us the information on safety and effectiveness that we will want to know once it goes on the market. At the same time we don’t want to over-complicate the clinical trial process and take too long to approve drugs that are doing well.
Billy Foster is in a clinical trial and has had a good response to the drug he is taking. Through his involvement with programs through the Kidney Cancer Association (KCA) and the American Association for Cancer Research (AACR) he has become aware of built-in disparities in the design of most clinical tri
Sorry we couldn't complete your registration. Please try again.
Please enter your email to finish creating your account.
Receive a personalized list of podcasts based on your preferences.